Can you take ace and arb together
Pro Research Analysisby 
Searched over 200M research papers
Can You Take ACE Inhibitors and ARBs Together?
Introduction to ACE Inhibitors and ARBs
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are commonly prescribed medications for managing conditions such as hypertension, heart failure, and chronic kidney disease. Both drug classes target the renin-angiotensin-aldosterone system (RAAS) but through different mechanisms. ACE inhibitors block the conversion of angiotensin I to angiotensin II, while ARBs block the receptors for angiotensin II. This article explores whether combining these two classes of drugs is beneficial and safe.
Efficacy of Combined Therapy in Heart Failure
Several studies have investigated the efficacy of combining ACE inhibitors and ARBs in patients with heart failure. A meta-analysis of randomized controlled trials found that while combination therapy did not significantly reduce overall mortality or all-cause hospitalization, it did reduce hospital admissions specifically for heart failure. However, this benefit came with an increased risk of adverse events such as worsening renal function and symptomatic hypotension.
Impact on Proteinuric Renal Disease
In patients with proteinuric renal disease, both ACE inhibitors and ARBs have been shown to reduce proteinuria, a marker of kidney damage. Combining these drugs appears to offer additional benefits in reducing proteinuria compared to monotherapy . However, the combination therapy was associated with a small but significant increase in serum potassium levels and a non-significant decrease in glomerular filtration rate (GFR). Long-term benefits on renal function preservation remain uncertain, necessitating further research.
Safety Concerns in Diabetic Nephropathy
The safety of combining ACE inhibitors and ARBs in diabetic nephropathy has been questioned. A study involving patients with type 2 diabetes and nephropathy found that combination therapy did not significantly improve renal outcomes compared to monotherapy but did increase the risk of hyperkalemia and acute kidney injury. This led to the early termination of the study due to safety concerns.
Use in Hypertension and COVID-19
For hypertensive patients, especially those with severe or lethal COVID-19, the use of ACE inhibitors and ARBs has been a topic of debate. A meta-analysis concluded that these medications do not increase the risk of severe or lethal COVID-19, supporting their continued use during the pandemic. However, the combination of ACE inhibitors and ARBs is generally not recommended as initial therapy for hypertension due to the potential for adverse effects.
Pediatric Considerations
The use of combination therapy in children is less well-studied. Limited pediatric literature suggests that while ACE inhibitors and ARBs are effective in treating hypertension and offer renoprotective effects, the safety and efficacy of their combination in children remain unclear. More research is needed to establish guidelines for pediatric use.
Conclusion
Combining ACE inhibitors and ARBs can offer specific benefits, such as reduced proteinuria and fewer heart failure hospitalizations, but these benefits come with increased risks of adverse events like hyperkalemia and renal dysfunction. Current evidence suggests that combination therapy should be reserved for patients who do not achieve adequate control with monotherapy and should be closely monitored for adverse effects. Further research is needed to clarify the long-term benefits and safety of this combination, particularly in specific populations such as children and those with diabetic nephropathy.
Sources and full results
Most relevant research papers on this topic